Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report

Código QR

Conversion from Positive to Negative EGFR Mutation due to Clonal Selection during Long-Term Treatment with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Case Report

A 77-year-old woman with postoperative recurrent non-small cell lung adenocarcinoma, which exhibited an epidermal growth factor receptor (EGFR) L858R mutation, was treated with gefitinib and erlotinib. Seven years after the start of treatment, the patient experienced a recurrence of malignant pleura...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Masatomo Ueda, Masashi Namba, Kentaro Tokumo, Tadashi Senoo, Wataru Okamoto, Masami Yamauchi, Noboru Hattori, Kazuhiko Sugiyama
Formato:	article
Lenguaje:	EN
Publicado:	Karger Publishers 2021
Materias:	epidermal growth factor receptor mutation gefitinib erlotinib non-small cell lung cancer mechanisms of resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b9403e50a0b0414485fc95a2df433686
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Erlotinib eradicates brain metastases from epidermal growth factor receptor mutant non-small cell lung cancer
por: Siavash Jabbari, et al.
Publicado: (2011)

Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study
por: Chin‐Chou Wang, et al.
Publicado: (2021)

Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway
por: Pan YH, et al.
Publicado: (2018)

Inhibition of EGFR Signaling Protects from Mucormycosis
por: Tonya N. Watkins, et al.
Publicado: (2018)

ANALYSIS OF IMMUNOHISTOCHEMICAL EXPRESSION OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) IN COLORECTAL CANCER
por: Ghazala Sadaf, et al.
Publicado: (2020)

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
por: Zhu VW, et al.
Publicado: (2019)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

Polyethylene Glycol-Coated Graphene Oxide Loaded with Erlotinib as an Effective Therapeutic Agent for Treating Nasopharyngeal Cancer Cells
por: Lan MY, et al.
Publicado: (2020)

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece
por: Mountzios G, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review
por: Xiao C, et al.
Publicado: (2021)

EGFR T790M: revealing the secrets of a gatekeeper
por: Ko B, et al.
Publicado: (2017)

Clinical Case of Toxic Epidermal Necrolysis
por: Radenkova-Saeva J., et al.
Publicado: (2017)

Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases
por: Ling-Ling Kong, et al.
Publicado: (2017)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Construction of an immunotoxin by linking a monoclonal antibody against the human epidermal growth factor receptor and a hemolytic toxin
por: AVILA,ANA D, et al.
Publicado: (2007)

Study of foliar epidermal anatomy of four pistachio rootstocks under water stress
por: Arzani,Kazem, et al.
Publicado: (2013)

COMPARATIVE FOLIAR EPIDERMAL MORPHOLOGY OF THE WEST AFRICAN SPECIES OF THE GENUS AFZELIA SMITH (LEGUMINOSAE: AESALPINIOIDEAE)
por: Babalola Kadiri,Akeem, et al.
Publicado: (2008)

Surface Engineering of Escherichia coli–Derived OMVs as Promising Nano-Carriers to Target EGFR-Overexpressing Breast Cancer Cells
por: Zahra Sepahdar, et al.
Publicado: (2021)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Epidermal Cyst on the Face of a Child, Clinically and Dermoscopically Mimicking Pilomatricoma
por: Jelena Krtanjek, et al.
Publicado: (2019)

Dermoscopy of Epidermization of Lip Indicating Focal Compact Sebaceous Metaplasia
por: Shailesh Malani, et al.
Publicado: (2021)

Assessment of molecular recognition element for the quantification of human epidermal growth factor using surface plasmon resonance
por: Rosti,Ira Amira, et al.
Publicado: (2013)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts
por: Sreeranganathan M, et al.
Publicado: (2017)

Osimertinib Re-challenge for EGFR-mutant NSCLC after  Osimertinib-induced Interstitial Lung Disease: A Case Report
por: Junjie GU, et al.
Publicado: (2021)

Epidermal Hyaluronan in Barrier Alteration-Related Disease
por: Céline Evrard, et al.
Publicado: (2021)

Cetuximab-Coated Thermo-Sensitive Liposomes Loaded with Magnetic Nanoparticles and Doxorubicin for Targeted EGFR-Expressing Breast Cancer Combined Therapy
por: Dorjsuren B, et al.
Publicado: (2020)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

Predictive effect of DCE-MRI and DWI in brain metastases from NSCLC
por: Ye Chengyu, et al.
Publicado: (2021)

A Pediatric Case of Papular Epidermal Nevus With “Skyline” Basal Cell Layer (PENS)
por: Federico E. Strambach, et al.
Publicado: (2019)

Impact of Sodium Dichloroacetate Alone and in Combination Therapies on Lung Tumor Growth and Metastasis
por: Aya Al-Azawi, et al.
Publicado: (2021)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang W, et al.
Publicado: (2020)

Linc00467 promotion of gastric cancer development by directly regulating miR-7-5p expression and downstream epidermal growth factor receptor
por: Li-Hao Deng, et al.
Publicado: (2021)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami S, et al.
Publicado: (2017)

Verrucous Epidermal Nevus: Dermatoscopy, Reflectance Confocal Microscopy and Histopathological Correlation
por: Anna Elisa Verzì, et al.
Publicado: (2019)

RANK-C Expression Sensitizes ER-Negative, EGFR-Positive Breast Cancer Cells to EGFR-Tyrosine Kinase Inhibitors (TKIs)
por: Chaido Sirinian, et al.
Publicado: (2021)

Penile epidermal inclusion cyst mimicking ectopic testis mass: A case report
por: Gugum Indra Firdaus, et al.
Publicado: (2022)